Heidelberg Pharma (ETR:HPHA) Third Quarter 2024 Results

Key Financial Results

• Revenue: €3.56m (up 59% from 3Q 2023).

• Net loss: €5.59m (down from €113.1k profit in 3Q 2023).

• €0.13 loss per share (down from €0.002 profit in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Heidelberg Pharma Earnings Insights

Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.

Performance of the market in Germany.

The company's shares are up 7.0% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Heidelberg Pharma (at least 2 which don't sit too well with us), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.